4.7 Article

Altering AAV tropism with mosaic viral capsids

Journal

MOLECULAR THERAPY
Volume 11, Issue 6, Pages 856-865

Publisher

CELL PRESS
DOI: 10.1016/j.ymthe.2005.03.005

Keywords

-

Funding

  1. NHLBI NIH HHS [P01 HL51811, P01 HL59412] Funding Source: Medline
  2. NIDDK NIH HHS [DK062345] Funding Source: Medline
  3. NIGMS NIH HHS [GM062234] Funding Source: Medline

Ask authors/readers for more resources

Over the past decade, AAV-based vectors have emerged as promising candidates for gene therapeutic applications. Despite the broad tropism of the first eight serotypes identified, certain cell types are refractory to transduction with AAV-based vectors. Furthermore, for certain applications the targeting of specific cell types is desirable. To improve on present methods to alter AAV2 tropism, we take advantage of AAV2 mosaics. Here, we show that AAV2 mosaics have improved infectivity compared with all-mutant virions. Using an AAV2 mutant that contains the immunoglobulin-binding Z34C fragment of protein A, we demonstrate the utility of AAV2 mosaics to alter AAV2 tropism. This system allows us to transduce selectively and efficiently MO7e and Jurkat cells. The use of AAV2 mosaics with a protein A fragment inserted into their capsid, together with targeting antibodies, is a versatile method that allows the specific transduction of a wide array of cell types.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available